Louise Ghesquière

Louise Ghesquière

Auto-generated profile, based on publicly available information

Louise Ghesquière

Reproduction, Mother and Child Health Unit, Research Center of the CHU de Québec, Université Laval, Québec City, Québec, Canada; Department of Obstetrics, Université de Lille, CHU de Lille, Lille, France

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Diabetes & Metabolism
Verified
Journal Article
Closed access
LGL. Ghesquière
L. Ghesquière
CGCharles Garabedian
Charles Garabedian
EDE. Drumez
E. Drumez
MLM. Lemaître
M. Lemaître
MCM. Cazaubiel
M. Cazaubiel
AVA. Vambergue
A. Vambergue

1 January 2021 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
AGA. Grabarz
A. Grabarz
LGL. Ghesquière
L. Ghesquière
VDV. Debarge
V. Debarge
NRN. Ramdane
N. Ramdane
VDV. Delporte
V. Delporte
CGC. Garabedian
C. Garabedian

13 October 2022 in British Journal of Anaesthesia
Verified
Journal Article
Open access
ADAnne-Sophie Ducloy-Bouthors
Anne-Sophie Ducloy-Bouthors
SGSixtine Gilliot
Sixtine Gilliot
MKMaeva Kyheng
Maeva Kyheng
DFDavid Faraoni
David Faraoni
ATAlexandre Turbelin
Alexandre Turbelin
PRPierre Richart
Pierre Richart
The optimal dose of tranexamic acid to inhibit hyperfibrinolysis in postpartum haemorrhage is unclear. Tranexamic Acid to Reduce Blood Loss in Hemorrhagic Cesarean Delivery (TRACES) was a double-blind, placebo-controlled, randomised, multicentre dose-ranging study to determine the dose–effect relationship for two regimens of intravenous tranexamic acid vs placebo. Women experiencing postpartum haemorrhage during Caesarean delivery were randomised to receive placebo (n=60), tranexamic acid 0.5 g (n=57), or tranexamic acid 1 g i.v. (n=58). Biomarkers of fibrinolytic activation were assayed at five time points, with inhibition of hyperfibrinolysis defined as reductions in the increase over baseline in D-dimer and plasmin–antiplasmin levels and in the plasmin peak time. In the placebo group, hyperfibrinolysis was evidenced by a mean increase over baseline [95% confidence interval] of 93% [68–118] for D-dimer level at 120 min and 56% [25–87] for the plasmin–antiplasmin level at 30 min. A dose of tranexamic acid 1 g was associated with smaller increases over baseline (D-dimers: 38% [13–63] [P=0.003 vs placebo]; plasmin–antiplasmin: –2% [–32 to 28] [P=0.009 vs placebo]). A dose of tranexamic acid 0.5 g was less potent, with non-significant reductions (D-dimers: 58% [32–84] [P=0.06 vs placebo]; plasmin–antiplasmin: 13% [18–43] [P=0.051]). Although both tranexamic acid doses reduced the plasmin peak, reduction in plasmin peak time was significant only for the 1 g dose of tranexamic acid. Fibrinolytic activation was significantly inhibited by a dose of intravenous tranexamic acid 1 g but not 0.5 g. Pharmacokinetic–pharmacodynamic modelling of these data might identify the best pharmacodynamic monitoring criteria and the optimal tranexamic acid dosing regimen for treatment of postpartum haemorrhage. NCT 02797119.

1 May 2018 in Journal of Gynecology Obstetrics and Human Reproduction
Verified
Journal Article
Closed access
LGL. Ghesquière
L. Ghesquière
CGC. Garabedian
C. Garabedian
CCC. Coulon
C. Coulon
PVP. Verpillat
P. Verpillat
TRT. Rakza
T. Rakza
VDV. Debarge
V. Debarge

19 December 2018 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Closed access
PDF file
LGLouise Ghesquière
Louise Ghesquière
JJJulien De Jonckheere
Julien De Jonckheere
EDElodie Drumez
Elodie Drumez
DSDyuti Sharma
Dyuti Sharma
EAEstelle Aubry
Estelle Aubry
CGCharles Garabedian
Charles Garabedian

8 September 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LGL. Ghesquière
L. Ghesquière
PDP. Deruelle
P. Deruelle
YRY. Ramdane
Y. Ramdane
CGC. Garabedian
C. Garabedian
CCC. Charley-Monaca
C. Charley-Monaca
ADA.-F. Dalmas
A.-F. Dalmas
Define the prevalence of OSA in a population of obese pregnant women. Secondary objectives were to assess its obstetric consequences and define its risk factors in this population. This single-center prospective study took place at the Lille University Hospital from 2010 to 2016 and included pregnant women with a body mass index (BMI) > 35 kg/m2. They underwent polysomnography (type 1 sleep testing) between 24 and 32 weeks of gestation to diagnose OSA. Clinical, obstetric, and fetal data were collected monthly and at delivery. We compared the groups with and without OSA and calculated its prevalence. This study included 67 women with a mean BMI of 42.4 ± 6.2 kg/m2. Among them, 29 had OSA, for a prevalence of 43.3% (95% confidence interval, 31.4–55.2); it was mild or moderate in 25 women and severe in 4. Comparison of the two groups showed that women in the OSA group were older (31.9 ± 4.7 years vs 29.5 ± 4.8 years, P = .045), had chronic hypertension more frequently (37.9% vs 7.9%, P = .0027), and had a higher mean BMI (43.8 ± 6.2 kg/m2 vs 41.2 ± 6 kg/m2, P = .045). During pregnancy, they developed gestational diabetes more often (48.3% vs 23.7%, P = .04). No significant differences were observed for any of the other criteria studied. The prevalence of OSA was high in our study, and women with it developed gestational diabetes during pregnancy more often. No other obstetric complications were observed.